RecruitingNCT03844399

(3D) Ultrasound Imaging Liver and Kidney

Use of 3-Dimensional (3D) Ultrasound Imaging to Guide the Treatment of Abdominal Tumours Using Focal Ablation or Biopsies


Sponsor

Western University, Canada

Enrollment

40 participants

Start Date

Oct 3, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This study is to assess the addition of 3D ultrasound guidance during standard care ablation or biopsies of liver or kidney tumours. 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-demensional volume , allowing area in question to be viewed in many different planes. 3D ultrasound is a safe, fast, non-invasive imaging procedure. Ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed or properly targeted during biopsy.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • • Patients who are scheduled for standard care liver or kidney ablation or biopsy

Exclusion Criteria1

  • None

Interventions

DEVICEAblation

The medical device will passively record image data during the standard care ablation

DEVICEBiopsy

The medical device will passively record image data during the standard care biopsy


Locations(1)

Victoria Hospital

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03844399


Related Trials